This chimera, containing HER2-Bcl2 siRNA, targets HER2 expressing cancer cells specifically and initiates the downregulation of the Bcl2 gene, thus opening a new combinational strategy against cancer [94]. This evidence concerns the gene BCL2 and cancer.